Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial

ConclusionsA single rectal omeprazole dose (1  mg/kg) results in consistent increases in intraesophageal and gastric pH in infants with EA- or CDH-related GERD, similar to an oral dose. Considering the challenges with existing oral formulations, rectal omeprazole presents as an innovative, promising alternative for infants with pathological GE RD.Clinical Trial RegisterClinicalTrials.gov Identifier: NCT00226044.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research